Featured Article

Dyslipidemia and Atherosclerosis Clinical Practice Guidelines

Dyslipidemia and Atherosclerosis Clinical Practice Guidelines

New guidelines for dyslipidemia management and atherosclerosis prevention include a wider range of disease stages and more aggressive intervention.

Latest Features

PCSK9 Inhibitor Alirocumab Associated With 75% Reduction in Apheresis

PCSK9 Inhibitor Alirocumab Associated With 75% Reduction in Apheresis

Among patients with heterozygous familial hypercholesterolemia, alirocumab was associated with a 75% reduction in lipoprotein apheresis compared with placebo.

Statins Limit Vaccine Efficacy of Influenza Strain

Statins Limit Vaccine Efficacy of Influenza Strain

Statin use modified vaccine effectiveness and influenza risk for A(H3N2) infection but not for A(H1N1).

Higher Vitamin D Levels May Related to Higher Total Cholesterol, HDL-C

Higher Vitamin D Levels May Related to Higher Total Cholesterol, HDL-C

Vitamin D may influence cardiovascular disease risk via its effect on lipid levels.

Considering Cardiovascular Risks of Antidiabetic Drugs

Considering Cardiovascular Risks of Antidiabetic Drugs

A review of current antidiabetic drug treatments available and their individual cardiovascular risk profiles.

PCSK9 Inhibitors: Breakthrough in LDL-C Reduction, But Comes at a Cost

PCSK9 Inhibitors: Breakthrough in LDL-C Reduction, But Comes at a Cost

PCSK9 inhibitors may offer hope to patients with familial hypercholesterolemia who cannot tolerate or achieve goal LDL-C levels with statins.

LATEST NEWS

PCSK9 Inhibitor Does Not Affect Cognitive Function

PCSK9 Inhibitor Does Not Affect Cognitive Function

Evolocumab is not associated with adverse cognitive effects even when low low-density lipoprotein cholesterol levels have been achieved.

Dyslipidemia in Children With HIV After Starting Antiretroviral Therapy

Dyslipidemia in Children With HIV After Starting Antiretroviral Therapy

Serum lipid profile changes were shown to occur within the first year of initiating antiretroviral therapy in children.

Coexisting COPD and Elevated CVD Risk May Benefit From Statins

Coexisting COPD and Elevated CVD Risk May Benefit From Statins

Researchers find statins could be a potential treatment option in COPD.

Less Than Half of Patients Prescribed PCSK9 Inhibitors Receive Approval

Less Than Half of Patients Prescribed PCSK9 Inhibitors Receive Approval

Less than half of patients prescribed PCSK9 inhibitors receive approval, and only about 30% ever receive therapy.

FDA Approves Pitavastatin for Mixed Dyslipidemia and Hyperlipidemia

FDA Approves Pitavastatin for Mixed Dyslipidemia and Hyperlipidemia

The FDA has approved a new pitavastatin for the treatment of primary hyperlipidemia or mixed dyslipidemia.

Anacetrapib Reduces Major Coronary Events When Added to Intensive Statin Therapy

Anacetrapib Reduces Major Coronary Events When Added to Intensive Statin Therapy

Lower incidence of major coronary events for patients with atherosclerotic vascular disease receiving intensive statins is linked with use of anacetrapib.

Cardiovascular Event Risk Better Predicted by ApoB vs LDL Cholesterol Level

Cardiovascular Event Risk Better Predicted by ApoB vs LDL Cholesterol Level

Clinical benefit of reduced low-density lipoprotein cholesterol (LDL-C) levels may depend on the corresponding reduction in apolipoprotein B (apoB)-containing lipoprotein particles.

Anti-Tumor Necrosis Factor Drug Improves CV Health in Psoriatic Arthritis

Anti-Tumor Necrosis Factor Drug Improves CV Health in Psoriatic Arthritis

Cardiovascular health in psoriatic arthritis improves with anti-tumor necrosis factor drug etanercept.

PCSK9 Inhibitor Evolocumab Continues to Lack Cost-Effectiveness

PCSK9 Inhibitor Evolocumab Continues to Lack Cost-Effectiveness

Findings for addition of evolocumab to standard tx in atherosclerotic cardiovascular disease

Antidepressant Mislabeled as Cholesterol Drug: Recall

Antidepressant Mislabeled as Cholesterol Drug: Recall

International Laboratories, LLC has issued a recall for one lot of Pravastatin Sodium Tablets 40mg due to mislabeling.

Sign Up for Free e-Newsletters